Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2022; 10(30): 11049-11058
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11049
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11049
Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports
Yun Zheng, Chen-Yu Zhu, Qiong Zhao, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310030, Zhejiang Province, China
Yun Zheng, Chen-Yu Zhu, Jing Lin, Wang-Shan Chen, Yu-Jie Wang, Hong-Ye Fu, Qiong Zhao, Department of Thoracic Oncology, Shulan (Hangzhou) Hospital affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310000, Zhejiang Province, China
Yu-Jie Wang, Hong-Ye Fu, Zhejiang Chinese Medical University, Hangzhou 311402, Zhejiang Province, China
Author contributions: Zheng Y and Zhu CY designed the study, drafted the manuscript, and reviewed the manuscript; Zheng Y, Zhu CY, and Lin J performed the literature review; Lin J was involved in supervision and manuscript review and editing; Chen WS contributed to the data curation and investigation; Wang YJ and Fu HY conducted the study and suggested pertinent modification; Zhao Q supervised the study process and reviewed the manuscript; and all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patients for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiong Zhao, PhD, Doctor, Zhejiang University School of Medicine, Zhejiang University, No. 866 Yuhangtang Road, Xihu District, Hangzhou 310030, Zhejiang Province, China. jade1972@126.com
Received: May 12, 2022
Peer-review started: May 12, 2022
First decision: June 16, 2022
Revised: July 9, 2022
Accepted: September 16, 2022
Article in press: September 16, 2022
Published online: October 26, 2022
Peer-review started: May 12, 2022
First decision: June 16, 2022
Revised: July 9, 2022
Accepted: September 16, 2022
Article in press: September 16, 2022
Published online: October 26, 2022
Core Tip
Core Tip: Hypophysitis induced by programmed cell death 1 protein (PD-1) inhibitor treatment in non-small cell lung cancer (NSCLC) was rarely reported. In this study, we report three patients with NSCLC who developed hypophysitis induced by PD-1 immune checkpoint inhibitor treatment. Our study suggested that unexpected fatigue, appetite decreases, nausea, vomiting, hoarse voice, bucking, and difficulty breathing were largely correlated with immune-related hypophysitis. We also found that the clinical prognosis of patients with hypophysitis was related to the dose of steroid therapy. This work provided a reference for the diagnosis and timely treatment of hypophysitis in the clinic.